Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (29281)	9/14/1999 11:06:00 AM
From: David Bogdanoff	Respond to of 32384

To all; I believe that the Thompson buy-sell indicators have been discussed in some detail on this thread. Therefore the following posting should be of interest: Message 11238776 david

To: Henry Niman who wrote (29281)	9/14/1999 12:12:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

Henry, I do not have an answer to your question about Roche getting a two-fer. It certainly is possible and that should become apparent over time. Nevertheless, I'm certain that LGND will enforce all of its intellectual property rights. Given the popularity of IL-2 and its receptor, as well as LGND's broad retinoid and rexinoid patents, I'm virtually certain we'll see more licensing deals in coming months. Any word on the timing of LLY's selection of a replacement compound? Best regards, Walter